-
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TWEAK with potent antitumor activity.
-
Salviolone is a natural diterpene identified from Salvia miltiorrhiza roots with an anti-melanoma activity.
-
ABT-510, a peptide analog of thrombospondin-1 (TSP-1), can block angiogenesis in vitro and in vivo, and slow tumor growth.
-
Indoximod, an immunometabolic adjuvant, is an orally active IDO pathway inhibitor. Indoximod acts as a Trp mimetic in regulating mTOR.
-
Lomeguatrib is a highly potent MGMT inactivator, improves the therapeutic effect of alkylating agents in a number of tumour models.
-
β-Lapachone, a topoisomerase I inhibitor, induces apoptosis by inhibiting cell cycle progression. β-Lapachone has anti-inflammatory effect.
-
Apitolisib is a potent Class I PI3 kinase and mTORC1/2 inhibitor with IC50s of 5 nM/27 nM/7 nM/14 nM for PI3Kα/β/δ/γ, respectively.
-
CBL0137 is an inhibitor of the histone chaperone, FACT. CBL0137 activates p53 and inhibits NF-κB with EC50s of 0.37 and 0.47 µM, respectively.
-
CX-5461 is a potent and orally bioavailable inhibitor of Pol I-mediated rRNA synthesis with potent antitumor activity.
-
Elesclomol is an oxidative stress inducer that induces cancer cell apoptosis. Elesclomol is a reactive oxygen species (ROS) inducer.
Categories
Diseases
Targets
Others
Archives
- January 2023 (2)
- November 2022 (1)
- February 2022 (2)
- January 2022 (1)
- December 2021 (2)
- October 2021 (2)
- September 2021 (1)
- June 2021 (1)
- February 2021 (1)
- January 2021 (2)
- December 2020 (3)
- November 2020 (1)
- October 2020 (1)
- August 2020 (1)
- June 2020 (1)
- February 2020 (1)
- November 2019 (2)
- October 2019 (4)
- September 2019 (1)
- August 2019 (7)
- July 2019 (2)
- June 2019 (1)
- April 2019 (2)
- March 2019 (1)